The Sway PR team today took on the big issues facing the biotech and pharma industries including Trump’s proposed NIH cuts which has the potential to slow the progress of rare disease development.
The story covers a Maryland family’s fight to cure their daughter’s rare disease, H-ABC, faces new hurdles amid proposed cuts to medical research.
Elouise Sloan, 19, has lived with the degenerative brain disorder since childhood, requiring constant care. Her parents, Michele and Britt Sloan, have become advocates and fundraisers.
Funding remains a major obstacle. Our client, Dan Williams, CEO of SynaptixBio, is developing a gene-silencing treatment for H-ABC
In the interview he talked about the investment landscape which has slowed significantly.
The company is seeking $24 million to begin clinical trials next year. Dan partly attributes the decline in biotech funding to recent U.S. political shifts.
The administration’s proposed $18 billion cut to the National Institutes of Health (NIH) budget has sparked criticism, with experts warning that such reductions threaten research and patient safety.
Check out Dan Williams, the CEO of SynaptixBio on the NBC news below:
Read the full story here Trump’s proposed cuts cause concern about rare disease research – NBC4 Washington